Surface Oncology Inc

NASDAQ:SURF   3:59:43 PM EDT
7.37
-0.18 (-2.45%)
Products, Other Pre-Announcement

Surface Oncology Announces Exclusive License Agreement With Gsk For Novel Immunotherapy Program

Published: 12/17/2020 12:01 GMT
Surface Oncology Inc (SURF) - Surface Oncology Announces Exclusive License Agreement With Gsk for Novel Immunotherapy Program.
Surface Oncology Inc - to Receive $85 Million Upfront Payment.
Surface Oncology - Gsk Will Have Exclusive Rights to Develop and Commercialize Srf813, a Novel Antibody Targeting Pvrig.
Surface Oncology Inc - Gsk to Exclusively License Worldwide Development and Commercial Rights to Surface Oncology's Preclinical Program Srf813.
Surface Oncology - Surface Oncology May Receive Up to an Additional $730 Million in Future Milestone Payments.
Surface Oncology - Projects Cash Runway Sufficient to Fund Its Operations Through 2023.